Thomas Viethen

766 total citations
15 papers, 218 citations indexed

About

Thomas Viethen is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Thomas Viethen has authored 15 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Cardiology and Cardiovascular Medicine and 2 papers in Internal Medicine. Recurrent topics in Thomas Viethen's work include Pulmonary Hypertension Research and Treatments (9 papers), Heart Failure Treatment and Management (3 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Thomas Viethen is often cited by papers focused on Pulmonary Hypertension Research and Treatments (9 papers), Heart Failure Treatment and Management (3 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Thomas Viethen collaborates with scholars based in Germany, United States and Brazil. Thomas Viethen's co-authors include Stephan Rosenkranz, Felix Gerhardt, Daniel Dumitrescu, Stephan Baldus, Henrik ten Freyhaus, Tanja K. Rudolph, Tilmann Kramer, Scott D. Solomon, Dalane W. Kitzman and Ákos F. Pap and has published in prestigious journals such as JAMA, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Thomas Viethen

15 papers receiving 215 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Viethen Germany 7 118 108 35 28 14 15 218
Mattias Ekström Sweden 10 141 1.2× 29 0.3× 23 0.7× 12 0.4× 53 3.8× 31 314
Monika Brand United States 8 117 1.0× 147 1.4× 3 0.1× 44 1.6× 30 2.1× 19 268
Don Thiwanka Wijeratne Canada 9 123 1.0× 201 1.9× 8 0.2× 18 0.6× 21 1.5× 27 333
M. Myśliwiec Poland 9 39 0.3× 55 0.5× 32 0.9× 9 0.3× 52 3.7× 30 261
Hans Hillege Netherlands 7 224 1.9× 25 0.2× 17 0.5× 7 0.3× 38 2.7× 13 296
Trejeeve Martyn United States 9 74 0.6× 53 0.5× 9 0.3× 13 0.5× 66 4.7× 43 244
Emre Yılmaz Türkiye 9 109 0.9× 36 0.3× 28 0.8× 6 0.2× 44 3.1× 47 263
Gema Fernández Juárez Spain 2 41 0.3× 92 0.9× 7 0.2× 10 0.4× 28 2.0× 7 255
Vincent ten Cate Germany 10 102 0.9× 24 0.2× 52 1.5× 32 1.1× 37 2.6× 35 249
Katarzyna Ptaszyńska‐Kopczyńska Poland 10 146 1.2× 88 0.8× 5 0.1× 14 0.5× 28 2.0× 25 258

Countries citing papers authored by Thomas Viethen

Since Specialization
Citations

This map shows the geographic impact of Thomas Viethen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Viethen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Viethen more than expected).

Fields of papers citing papers by Thomas Viethen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Viethen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Viethen. The network helps show where Thomas Viethen may publish in the future.

Co-authorship network of co-authors of Thomas Viethen

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Viethen. A scholar is included among the top collaborators of Thomas Viethen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Viethen. Thomas Viethen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Eikelboom, John W., Hardi Mundl, John H. Alexander, et al.. (2024). Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83(6). 669–678. 4 indexed citations
3.
Sarraju, Ashish, Thomas Viethen, Hardi Mundl, et al.. (2022). Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). npj Digital Medicine. 5(1). 80–80. 14 indexed citations
4.
Parameswaran, V., Udhayvir Singh Grewal, Thomas Viethen, et al.. (2021). Validation of a pandemic-proof, decentralized cardiovascular trial: scalable design produces rapid recruitment, high engagement and protocol adherence in DeTAP (Decentralized Trial in Afib Patients). European Heart Journal. 42(Supplement_1). 6 indexed citations
5.
Kramer, Tilmann, Felix Gerhardt, Henrik ten Freyhaus, et al.. (2021). Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study. Journal of Cachexia Sarcopenia and Muscle. 12(6). 1501–1512. 23 indexed citations
6.
Shah, Sanjiv J., Adriaan A. Voors, John J.V. McMurray, et al.. (2019). Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 321(21). 2101–2101. 46 indexed citations
7.
Dumitrescu, D., Tilmann Kramer, Felix Gerhardt, et al.. (2018). P1624Intravenous iron substitution improves pulmonary diffusion capacity in patients with iron deficiency and precapillary pulmonary hypertension. European Heart Journal. 39(suppl_1). 1 indexed citations
8.
Gerhardt, Felix, Daniel Dumitrescu, Thomas Viethen, et al.. (2017). Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. Heart. 103(8). 592–598. 30 indexed citations
9.
Dumitrescu, D., Tilmann Kramer, Felix Gerhardt, et al.. (2017). P3531Improvement of pulmonary diffusion capacity after intravenous iron substitution in patients with iron deficiency and pulmonary hypertension. European Heart Journal. 38(suppl_1). 1 indexed citations
10.
Grünig, Ekkehard, Nicola Benjamin, Tobias Lange, et al.. (2016). Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial. Respiration. 92(6). 362–370. 13 indexed citations
11.
Dumitrescu, Daniel, Felix Gerhardt, Thomas Viethen, et al.. (2016). Case report: Subjective loss of performance after pulmonary embolism in an athlete– beyond normal values. BMC Pulmonary Medicine. 16(1). 21–21. 4 indexed citations
12.
Egenlauf, Benjamin, Ekkehard Grünig, Nicola Benjamin, et al.. (2016). Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial.. Pneumologie. 70(S 01). 3 indexed citations
13.
Grünig, Ekkehard, Benjamin Egenlauf, Tobias Lange, et al.. (2015). Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH). PA2114–PA2114. 1 indexed citations
14.
Viethen, Thomas, Felix Gerhardt, Daniel Dumitrescu, et al.. (2014). Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study. International Journal of Cardiology. 175(2). 233–239. 67 indexed citations
15.
Dumitrescu, D., Felix Gerhardt, Thomas Viethen, Erland Erdmann, & Stephan Rosenkranz. (2011). 70-jährige Patientin mit Myokardhypertrophie und schwerer pulmonaler Hypertonie: Prä- oder postkapillär?. DMW - Deutsche Medizinische Wochenschrift. 136(50). 2594–2598. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026